Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.

Queval CJ, Song OR, Deboosère N, Delorme V, Debrie AS, Iantomasi R, Veyron-Churlet R, Jouny S, Redhage K, Deloison G, Baulard A, Chamaillard M, Locht C, Brodin P.

Sci Rep. 2016 Jul 7;6:29297. doi: 10.1038/srep29297.

2.

A Macrophage Infection Model to Predict Drug Efficacy Against Mycobacterium Tuberculosis.

Schaaf K, Hayley V, Speer A, Wolschendorf F, Niederweis M, Kutsch O, Sun J.

Assay Drug Dev Technol. 2016 Aug;14(6):345-54. doi: 10.1089/adt.2016.717. Epub 2016 Jun 21.

PMID:
27327048
3.

Oxadiazoles Have Butyrate-Specific Conditional Activity against Mycobacterium tuberculosis.

Early JV, Casey A, Martinez-Grau MA, Gonzalez Valcarcel IC, Vieth M, Ollinger J, Bailey MA, Alling T, Files M, Ovechkina Y, Parish T.

Antimicrob Agents Chemother. 2016 May 23;60(6):3608-16. doi: 10.1128/AAC.02896-15. Print 2016 Jun.

PMID:
27044545
4.

The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.

Evans JC, Mizrahi V.

Front Microbiol. 2015 Aug 4;6:812. doi: 10.3389/fmicb.2015.00812. eCollection 2015. Review.

5.

Next-generation antimicrobials: from chemical biology to first-in-class drugs.

Ang ML, Murima P, Pethe K.

Arch Pharm Res. 2015 Sep;38(9):1702-17. doi: 10.1007/s12272-015-0645-0. Epub 2015 Aug 11. Review.

6.

Whole-genome sequencing targets drug-resistant bacterial infections.

Punina NV, Makridakis NM, Remnev MA, Topunov AF.

Hum Genomics. 2015 Aug 5;9:19. doi: 10.1186/s40246-015-0037-z. Review.

7.

The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.

Makarov V, Neres J, Hartkoorn RC, Ryabova OB, Kazakova E, Šarkan M, Huszár S, Piton J, Kolly GS, Vocat A, Conroy TM, Mikušová K, Cole ST.

Antimicrob Agents Chemother. 2015 Aug;59(8):4446-52. doi: 10.1128/AAC.00778-15. Epub 2015 May 18.

8.

New insights into TB physiology suggest untapped therapeutic opportunities.

Baer CE, Rubin EJ, Sassetti CM.

Immunol Rev. 2015 Mar;264(1):327-43. doi: 10.1111/imr.12267. Review.

9.

Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043.

Tiwari R, Miller PA, Cho S, Franzblau SG, Miller MJ.

ACS Med Chem Lett. 2014 Nov 29;6(2):128-33. doi: 10.1021/ml5003458. eCollection 2015 Feb 12.

10.

The future for early-stage tuberculosis drug discovery.

Zuniga ES, Early J, Parish T.

Future Microbiol. 2015;10(2):217-29. doi: 10.2217/fmb.14.125. Review.

11.

Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.

Simeone R, Sayes F, Song O, Gröschel MI, Brodin P, Brosch R, Majlessi L.

PLoS Pathog. 2015 Feb 6;11(2):e1004650. doi: 10.1371/journal.ppat.1004650. eCollection 2015 Feb.

12.

Biochemical and structural characterization of mycobacterial aspartyl-tRNA synthetase AspS, a promising TB drug target.

Gurcha SS, Usha V, Cox JA, Fütterer K, Abrahams KA, Bhatt A, Alderwick LJ, Reynolds RC, Loman NJ, Nataraj V, Alemparte C, Barros D, Lloyd AJ, Ballell L, Hobrath JV, Besra GS.

PLoS One. 2014 Nov 19;9(11):e113568. doi: 10.1371/journal.pone.0113568. eCollection 2014.

13.

High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.

Silva-Miranda M, Ekaza E, Breiman A, Asehnoune K, Barros-Aguirre D, Pethe K, Ewann F, Brodin P, Ballell-Pages L, Altare F.

Antimicrob Agents Chemother. 2015 Jan;59(1):693-7. doi: 10.1128/AAC.03705-14. Epub 2014 Oct 27.

14.

The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo.

Boldrin F, Ventura M, Degiacomi G, Ravishankar S, Sala C, Svetlikova Z, Ambady A, Dhar N, Kordulakova J, Zhang M, Serafini A, Vishwas KG, Kolly GS, Kumar N, Palù G, Guerin ME, Mikusova K, Cole ST, Manganelli R.

J Bacteriol. 2014 Oct;196(19):3441-51. doi: 10.1128/JB.01346-13. Epub 2014 Jul 21. Erratum in: J Bacteriol. 2014 Dec;196(23):4197. Vishwas, V G [Corrected to Vishwas, K G].

15.

The cell envelope glycoconjugates of Mycobacterium tuberculosis.

Angala SK, Belardinelli JM, Huc-Claustre E, Wheat WH, Jackson M.

Crit Rev Biochem Mol Biol. 2014 Sep-Oct;49(5):361-99. doi: 10.3109/10409238.2014.925420. Epub 2014 Jun 10. Review.

16.

A high-content imaging assay for the quantification of the Burkholderia pseudomallei induced multinucleated giant cell (MNGC) phenotype in murine macrophages.

Pegoraro G, Eaton BP, Ulrich RL, Lane DJ, Ojeda JF, Bavari S, DeShazer D, Panchal RG.

BMC Microbiol. 2014 Apr 22;14:98. doi: 10.1186/1471-2180-14-98.

17.

Increasing the Content of High-Content Screening: An Overview.

Singh S, Carpenter AE, Genovesio A.

J Biomol Screen. 2014 Jun;19(5):640-50. doi: 10.1177/1087057114528537. Epub 2014 Apr 7. Review.

18.

Identification of host-targeted small molecules that restrict intracellular Mycobacterium tuberculosis growth.

Stanley SA, Barczak AK, Silvis MR, Luo SS, Sogi K, Vokes M, Bray MA, Carpenter AE, Moore CB, Siddiqi N, Rubin EJ, Hung DT.

PLoS Pathog. 2014 Feb 20;10(2):e1003946. doi: 10.1371/journal.ppat.1003946. eCollection 2014 Feb.

19.

Tuberculosis drug discovery in the post-post-genomic era.

Lechartier B, Rybniker J, Zumla A, Cole ST.

EMBO Mol Med. 2014 Feb;6(2):158-68. doi: 10.1002/emmm.201201772. Epub 2014 Jan 8. Review.

20.

Whole-cell screening-based identification of inhibitors against the intraphagosomal survival of Mycobacterium tuberculosis.

Khare G, Kumar P, Tyagi AK.

Antimicrob Agents Chemother. 2013 Dec;57(12):6372-7. doi: 10.1128/AAC.01444-13. Epub 2013 Sep 23.

Items per page

Supplemental Content

Write to the Help Desk